Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | LPL | P06858 | 5/20 | 0.62 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869828 | 0.91 | LPL (0.61) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL257769 | 0.82 | CA4 (0.59) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL257833 | 0.81 | FFAR1 (0.59) | CA1CA2TRPV1 | |
| SCHEMBL890400 | 0.81 | LPL (0.73) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL18377315 | 0.81 | CA1 (0.62) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL9069707 | 0.81 | HTR2A (0.75) | HTR2A | |
| SCHEMBL103396 | 0.80 | CA2 (0.67) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL257908 | 0.80 | FFAR1 (0.60) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL12663116 | 0.79 | TDP1 (0.72) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL21384773 | 0.78 | CA1 (0.64) | CA1CA2LPLLIPGTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | disclosed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885LPL 180/4885 |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | CA1 3882/4885CA2 1744/4885LPL 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.